Public Sector Pension Investment Board Boosts Stock Position in Qiagen N.V. $QGEN

Public Sector Pension Investment Board raised its stake in shares of Qiagen N.V. (NYSE:QGEN) by 12.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 126,594 shares of the company’s stock after purchasing an additional 13,548 shares during the period. Public Sector Pension Investment Board owned 0.06% of Qiagen worth $5,607,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its stake in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock worth $39,000 after buying an additional 830 shares in the last quarter. MAI Capital Management grew its position in Qiagen by 998.9% in the 2nd quarter. MAI Capital Management now owns 978 shares of the company’s stock valued at $47,000 after acquiring an additional 889 shares in the last quarter. Allworth Financial LP lifted its holdings in Qiagen by 260.1% during the 2nd quarter. Allworth Financial LP now owns 1,102 shares of the company’s stock worth $53,000 after buying an additional 796 shares in the last quarter. GAMMA Investing LLC increased its holdings in Qiagen by 375.5% during the 3rd quarter. GAMMA Investing LLC now owns 1,241 shares of the company’s stock worth $55,000 after purchasing an additional 980 shares during the period. Finally, Cullen Frost Bankers Inc. grew its holdings in Qiagen by 13,144.4% during the 2nd quarter. Cullen Frost Bankers Inc. now owns 1,192 shares of the company’s stock worth $57,000 after acquiring an additional 1,183 shares in the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Analyst Ratings Changes

Several research firms have issued reports on QGEN. TD Cowen restated a “hold” rating on shares of Qiagen in a research note on Friday, February 6th. Citigroup cut their target price on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating for the company in a research report on Friday, February 6th. UBS Group set a $52.00 target price on shares of Qiagen in a research note on Monday, February 9th. Jefferies Financial Group restated a “buy” rating and issued a $59.00 price objective on shares of Qiagen in a report on Thursday, February 5th. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Qiagen in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company’s stock. According to data from MarketBeat, Qiagen presently has a consensus rating of “Hold” and a consensus target price of $55.20.

Qiagen Stock Performance

QGEN stock opened at $49.05 on Thursday. The stock’s 50 day simple moving average is $49.86 and its 200 day simple moving average is $49.49. Qiagen N.V. has a 12-month low of $39.61 and a 12-month high of $57.81. The firm has a market cap of $10.36 billion, a P/E ratio of 24.33, a P/E/G ratio of 2.38 and a beta of 0.67. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44.

Qiagen (NYSE:QGEN) last released its earnings results on Thursday, February 5th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a net margin of 20.33% and a return on equity of 14.56%. The firm had revenue of $540.42 million during the quarter, compared to analyst estimates of $528.53 million. During the same quarter in the previous year, the firm earned $0.61 earnings per share. The firm’s revenue for the quarter was up 3.6% compared to the same quarter last year. As a group, equities research analysts predict that Qiagen N.V. will post 2.26 EPS for the current year.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.